Literature DB >> 12810175

Serum levels of osteoprotegerin increase with age in a healthy adult population.

S Kudlacek1, B Schneider, W Woloszczuk, P Pietschmann, R Willvonseder.   

Abstract

Regulation of the balance of osteoblastic and osteoclastic activity is critical for the understanding of normal cell biology and forms the basis of metabolic bone diseases. Our study reports about influences of age and gender on serum levels of osteoprotegerin (OPG) and its association to other clinical parameters of bone metabolism in a precisely determined cohort of 1134 healthy subjects at 17 Austrian outpatient bone clinics, aged between 19 and 96 years (females n = 687, 50 +/- 21 years, 19-94, and males n = 447, 52 +/- 13.5 years, 24-96). Mean OPG serum levels for all participants were 50.83 +/- 51.47 pg/ml (n = 1134; median 36, 2-584) and we observed a sharp increase in females after 60 years and in males after 70 years of age. OPG serum levels increased significantly by age, 2.1 pg/ml in females and 1.9 pg/ml in males for every year (P < 0.0001). Correlation of OPG serum levels and several bone parameters of bone metabolism showed that OPG negatively correlated with serum iPTH (r = -0.14; P < 0.001) and with serum estradiol in females (r = -0.16, P < 0.0001). Bone mineral density measured by DXA method at the spine and at the hip did not correlate with OPG serum levels, except a borderline negative correlation at the trochanteric region (r = -0.1, P < 0.05) in females only. Our results show a significant increase of osteoprotegerin with age in healthy females and males but fluctuations do not predict bone mineral density under in vivo conditions.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 12810175     DOI: 10.1016/s8756-3282(03)00090-5

Source DB:  PubMed          Journal:  Bone        ISSN: 1873-2763            Impact factor:   4.398


  50 in total

1.  The contribution of serum osteoprotegerin to bone mass and vertebral fractures in postmenopausal women.

Authors:  Pedro Mezquita-Raya; Magdalena de la Higuera; Diego Fernández García; Guillermo Alonso; María Estrella Ruiz-Requena; Juan de Dios Luna; Fernando Escobar-Jiménez; Manuel Muñoz-Torres
Journal:  Osteoporos Int       Date:  2005-02-12       Impact factor: 4.507

2.  Osteoprotegerin and fractures in men and women with chronic kidney disease.

Authors:  Sarah L West; Charmaine E Lok; Sophie A Jamal
Journal:  J Bone Miner Metab       Date:  2014-07       Impact factor: 2.626

Review 3.  [Osteoporosis in men receiving androgen deprivation therapy for non-metastatic prostate cancer].

Authors:  Stefan Kudlacek; Thomas Puntus
Journal:  Wien Med Wochenschr       Date:  2012-08-09

4.  Association between Osteoprotegerin and Charcot Neuroarthropathy: a systematic review.

Authors:  Renata Ochoa-Précoma; Blanca T Pacheco-Soto; Leonardo M Porchia; Enrique Torres-Rasgado; Ricardo Pérez-Fuentes; M Elba Gonzalez-Mejia
Journal:  Acta Diabetol       Date:  2021-01-04       Impact factor: 4.280

5.  Plasma and drainage fluid levels of soluble receptor activator of nuclear factor-kB (sRANK), soluble receptor activator of nuclear factor-kB ligand (sRANKL) and osteoprotegerin (OPG) during proximal humerus fracture healing.

Authors:  Alessandra Colombini; Giovanni Lombardi; Emanuela Galliera; Giada Dogliotti; Pietro Randelli; Alexander Meerssemann; Giuseppe Mineo; Paolo Cabitza; Massimiliano Marco Corsi
Journal:  Int Orthop       Date:  2010-07-11       Impact factor: 3.075

Review 6.  Genetic epidemiology of age-related osteoporosis and its clinical applications.

Authors:  Ching-Lung Cheung; Su-Mei Xiao; Annie W C Kung
Journal:  Nat Rev Rheumatol       Date:  2010-08-03       Impact factor: 20.543

7.  Serum osteoprotegerin is increased and independently associated with coronary-artery atherosclerosis in patients with rheumatoid arthritis.

Authors:  Yu Asanuma; Cecilia P Chung; Annette Oeser; Joseph F Solus; Ingrid Avalos; Tebeb Gebretsadik; Ayumi Shintani; Paolo Raggi; Tuulikki Sokka; Theodore Pincus; C Michael Stein
Journal:  Atherosclerosis       Date:  2007-06-14       Impact factor: 5.162

8.  Curcumin improves regulatory T cells in gut-associated lymphoid tissue of colitis mice.

Authors:  Hai-Mei Zhao; Rong Xu; Xiao-Ying Huang; Shao-Min Cheng; Min-Fang Huang; Hai-Yang Yue; Xin Wang; Yong Zou; Ai-Ping Lu; Duan-Yong Liu
Journal:  World J Gastroenterol       Date:  2016-06-21       Impact factor: 5.742

9.  Bone loss in relation to serum levels of osteoprotegerin and nuclear factor-kappaB ligand: the Tromsø Study.

Authors:  L Jørgensen; A Vik; N Emaus; J Brox; J-B Hansen; E Mathiesen; P Vestergaard
Journal:  Osteoporos Int       Date:  2009-08-22       Impact factor: 4.507

10.  No significant effect on bone mineral density by high doses of vitamin D3 given to overweight subjects for one year.

Authors:  Rolf Jorde; Monica Sneve; Peter A Torjesen; Yngve Figenschau; John-Bjarne Hansen; Guri Grimnes
Journal:  Nutr J       Date:  2010-01-07       Impact factor: 3.271

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.